Novo Nordisk Issued Subpoena Over Marketing of Diabetes Drugs

Novo Nordisk has been hit with a subpoena from the U.S. Attorney in Massachusetts seeking information on the company’s marketing and promotion practices for several of its products. The government’s request indicates it is looking into potential criminal offenses surrounding Novo’s diabetes treatments NovoLog (insulin aspart), Levemir (insulin detemir recombinant) and Victoza (liraglutide), Novo said Wednesday. A Novo spokesman declined to comment further on the subpoena, but the company says it intends to cooperate with the U.S. Attorney’s investigation.
Washington Drug Letter